In practice, this suggests that women with ER+ HER2 positive breast cancers should be advised that they are unlikely to harbour a BRCA1/2 mutation unless there are other very suggestive features in their own personal or family histories (other more typical breast cancer or ovarian cancer). This evidence concerns the gene ERBB2 and ovarian cancer.